TP53 and acute lymphoblastic leukemia: Unlike most global cytogenomic studies in ALL, which do not routinely assess large‐scale deletions, our approach systematically screened TSGs including CDKN2A/B, TP53, RB1, ATM, and ETV6 [40, 41, 42].